Condition: Respiratory Syncytial Virus · Respiratory Syncytial Virus, Human · Sponsor: University of Oxford
This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated Respiratory Syncytial Virus (RSV), to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential adaptive platform trial, we will assess and compare the performance of currently licensed interventions (including repurposed drugs) with activity against RSV, and those with potential activity demonstrated in pre-clinical and early clinical studies relative to each-other, and the control (no antiviral treatment). ARSYNAL-FC study is funded by Wellcome Trust Grant ref: 226933/Z/23/Z through the COVID-19 Therapeutics Accelerator
This description comes directly from the study's public registry record.
William Schilling, MD · +662 203 6333 · william@tropmedres.ac
Nicholas J White, Prof · +662 203 6333 · nickw@tropmedres.ac
Always discuss trial participation with your own doctor first.
| Laos-Oxford-Mahosot Hospital-Wellcome Trust Research Unit | Vientiane, Laos | Recruiting |
| Faculty of Tropical Medicine, Mahidol University | Bangkok, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06488300